/
MESO
$13.61+$0.42 (+3.18%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.7B
129M shares
52-week range
$10.32 – $21.50
29% from low
Exchange
NASDAQ
ADRC
Borrow rate
10.55%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1.35
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3M | $16.7M | $32.2M | $7.5M | $10.2M | $7.5M | $5.9M | $17.2M |
| Cost of revenue | $5.5M | $75.2M | $81.5M | $85.7M | $63.6M | $54.9M | $41.1M | $5.1M |
| Gross profit | $11.8M | −$58.5M | −$49.3M | −$78.3M | −$53.4M | −$47.4M | −$35.2M | $12.1M |
| Gross margin | 68.2% | -349.5% | -153.4% | -1049.8% | -522.6% | -632.2% | -595.9% | 70.2% |
| R&D | $65.9M | $59.8M | $56.2M | $53.0M | $32.8M | $27.2M | $25.4M | $34.8M |
| Operating income | −$77.3M | −$80.2M | −$74.9M | −$109.1M | −$80.6M | −$69.3M | −$84.1M | −$62.4M |
| EBITDA | −$74.7M | −$84.5M | −$69.0M | −$84.7M | −$76.6M | −$58.5M | −$56.1M | −$73.7M |
| Net income | −$35.3M | −$89.8M | −$77.9M | −$98.8M | −$91.3M | −$81.9M | −$88.0M | −$102.1M |
| Net margin | -203.5% | -537.0% | -242.4% | -1325.3% | -894.6% | -1091.7% | -1490.3% | -593.9% |
| EPS (diluted) | -0.76 | -1.80 | -1.50 | -1.60 | -1.30 | -0.98 | -0.89 | -0.84 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $123M | $-0.34 | $-0.40–$-0.29 | 2 |
| 2027 | $200M | $0.07 | $0.05–$0.09 | 1 |
| 2028 | $303M | $0.72 | $0.56–$0.97 | 1 |
| 2029 | $619M | $2.12 | $1.64–$2.85 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Mesoblast Limited American Depositary Shares
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
www.mesoblast.com- Employees
- 81
- IPO / List date
- Jan 5, 2009
Held by traders on TradeandTell
No one on the platform currently holds MESO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MESO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-01-10 | 1-for-2reverse |
Recent trades on TradeandTell
No one on the platform has traded MESO yet.
